4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) operates in the Drug Manufacturers - General industry and is headquartered in Indore, India with about 1,752 employees. Its market capitalization is roughly ₹70 billion. In the fiscal year ended 2026-03-31, SYMBIOTEC reported ₹8.7B in revenue and ₹1.1B in net income.
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Revenue | ₹8.7B | ₹7.5B | ₹7.2B | ₹5.5B |
| Gross Profit | ₹5.5B | ₹4.5B | ₹4.0B | ₹2.4B |
| Operating Income (EBIT) | ₹1.8B | ₹1.6B | ₹1.3B | ₹442M |
| Net Income | ₹1.1B | ₹968M | ₹1.0B | ₹235M |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2025-06-30 |
|---|---|
| Total Revenue | ₹2.0B |
| Gross Profit | ₹1.2B |
| Operating Income (EBIT) | ₹478M |
| Net Income | ₹299M |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Assets | ₹17.8B | ₹15.8B | ₹12.9B | ₹9.9B |
| Total Liabilities | ₹6.3B | ₹7.6B | ₹5.8B | ₹3.7B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SYMBIOTEC viewer.
About TickerBase · Data methodology & sources · Privacy · Terms